Fasudil with immunotherapy for advanced prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a combination of fasudil hydrochloride and immunotherapy for men with metastatic castration-resistant prostate cancer that has stopped responding to chemotherapy and hormone therapy. The goal is to see if this new approach can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 84 years old.
- You have metastatic castration-resistant prostate cancer that has spread to bones or other organs.
- You have tried at least one chemotherapy with docetaxel and one newer hormone therapy, and these treatments no longer work.
- Your PSA level is rising, and you have new or growing tumors on scans.
- You are in generally good health, with expected survival of at least 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests combining a focused ultrasound treatment (high-intensity focused ultrasound) with a new type of hormone therapy for men with advanced prostate cancer that has spread. The goal is to see if this combination can help control the cancer better than hormone therapy alone.
This trial tests a combination of high-dose testosterone with enzalutamide and difluoromethylornithine (DFMO) for men whose prostate cancer has spread and stopped responding to standard hormone therapy. It aims to see if this approach can shrink tumors or slow the cancer's growth.
This trial tests a combination of hormone therapy, chemotherapy (docetaxel), and a targeted drug (apalutamide) with a focused ultrasound procedure (HIFU) for men with prostate cancer that has spread to many bones or organs. It may help control the cancer more effectively.
This early-stage trial tests a new drug (QLF4113) designed to help the immune system fight metastatic castration-resistant prostate cancer—a type that has spread and stopped responding to standard hormone therapy. You may qualify if you've already tried other treatments and your overall health is stable enough for the study.
This trial tests a new combination of two drugs, gedatolisib and darolutamide, in men with prostate cancer that has spread and stopped responding to hormone therapy. The goal is to see if the combination can help control the cancer when standard treatments have stopped working.
This trial tests a combination of hormone therapy, a targeted pill (Darolutamide), and an immunotherapy drug (Pembrolizumab) before and after surgery for men with high-risk prostate cancer that has specific genetic features. The goal is to see if this approach helps prevent the cancer from coming back.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.